Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Gray matter SWI-filtered phase and atrophy are linked to disability in MS .
Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results.
Regulation of prefrontal cortex myelination by the microbiota.
A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis.
Interferon-β-1b: a review of its use in multiple sclerosis.
Limit cycle oscillations in standing human posture.
Merck: Regulatory Update on Cladribine Tablets
IL-17 and GM-CSF Expression Are Antagonistically Regulated by Human T Helper Cells.
Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b.
The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro.
Translating state-of-the-art spinal cord MRI techniques to clinical use: A systematic review of clinical studies utilizing DTI, MT, MWF, MRS, and fMRI.
Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.
Neuronal expression of pathological tau accelerates oligodendrocyte progenitor cell differentiation.
Biologics-induced autoimmune diseases.
Flupirtine
NF-κB transcriptional activation by TNFα requires phospholipase C, extracellular signal-regulated kinase 2 and poly(ADP-ribose) polymerase-1.
Glatiramer acetate (GA) prevents TNF-α-induced monocyte adhesion to primary endothelial cells through interfering with the NF-κB pathway.
Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.
Differential Reconstitution of T Cell Subsets following Immunodepleting Treatment with Alemtuzumab (Anti-CD52 Monoclonal Antibody) in Patients with Relapsing-Remitting Multiple Sclerosis.
Gordon Research Conference on Synaptic Dysfunction and Neurodegeneration
Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients.
Biogen Idec receives notification of PDUFA date extension for PLEGRIDY™ (peginterferon beta-1a)
Molecular characterization of a peripheral receptor for cannabinoids.
CCR2 defines in vivo development and homing of IL-23-driven GM-CSF-producing Th17 cells.
Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.

Pages